Kiniksa Pharmaceuticals International, plc
KNSA
$56.51
-$2.03-3.47%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 214.27M | 202.13M | 180.86M | 156.80M | 137.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 214.27M | 202.13M | 180.86M | 156.80M | 137.79M |
| Cost of Revenue | 96.37M | 90.98M | 83.56M | 71.02M | 61.66M |
| Gross Profit | 117.89M | 111.15M | 97.29M | 85.78M | 76.13M |
| SG&A Expenses | 61.15M | 56.78M | 49.10M | 46.86M | 43.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 185.00M | 182.36M | 156.83M | 136.64M | 124.51M |
| Operating Income | 29.27M | 19.77M | 24.02M | 20.16M | 13.27M |
| Income Before Tax | 32.68M | 23.27M | 27.16M | 22.88M | 15.57M |
| Income Tax Expenses | 10.09M | 9.07M | 8.72M | 5.05M | 7.03M |
| Earnings from Continuing Operations | 22.59M | 14.20M | 18.44M | 17.83M | 8.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.59M | 14.20M | 18.44M | 17.83M | 8.54M |
| EBIT | 29.27M | 19.77M | 24.02M | 20.16M | 13.27M |
| EBITDA | 29.74M | 20.24M | 24.41M | 20.52M | 13.62M |
| EPS Basic | 0.30 | 0.19 | 0.25 | 0.24 | 0.12 |
| Normalized Basic EPS | 0.27 | 0.19 | 0.23 | 0.19 | 0.13 |
| EPS Diluted | 0.27 | 0.18 | 0.23 | 0.23 | 0.11 |
| Normalized Diluted EPS | 0.25 | 0.18 | 0.21 | 0.18 | 0.13 |
| Average Basic Shares Outstanding | 76.52M | 75.97M | 74.71M | 73.44M | 72.65M |
| Average Diluted Shares Outstanding | 82.41M | 81.57M | 80.04M | 77.94M | 76.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |